onAIRR 4: Understanding and engineering immune repertoires with Dr. Jacob Glanville

Dr. Jacob Glanville is founder and CEO of Centivax and  founder of Distributed Bio, acquired by Charles River in 2021. His work focuses on understanding and engineering  the repertoires of T and B cells to improve the response to pathogens. In this episode we discuss how to analyze receptor specificity and use this to create therapeutic antibodies and optimize vaccine response.

AIRR Community Meeting VI: “Exploring New Frontiers”: https://www.antibodysociety.org/the-airr-community/meetings/airr-community-meeting-vi-exploring-new-frontiers

iReceptor+ Seminar Series: http://www.ireceptor-plus.com/news-and-events/seminars

Comments are welcome to the inbox of onairr@airr-community.org or on social media under the hashtag #onAIRR. Further information can be found here: https://www.antibodysociety.org/the-airr-community/airr-c-podcast

• Likes
• Download 115
• Share